

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/142002 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/00 (2006.01)

C07K 16/28 (2006.01)

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2021/012329

(22) International Filing Date:

06 January 2021 (06.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/957,758 06 January 2020 (06.01.2020) US

62/985,152 04 March 2020 (04.03.2020) US

63/198,803 13 November 2020 (13.11.2020) US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: VACCINEX, INC. [US/US]; 1895 Mount
Hope Avenue, Rochester, New York 14620 (US).

(72) Inventors: HOLLAND, Pamela M.; c/o Surface Oncology,
Inc., 50 Hampshire Street, 8th Fl., Cambridge, Massa-
chusetts 02139 (US). LAKE, Andrew; c/o Surface Oncol-
ogy, Inc., 50 Hampshire Street, 8th Fl., Cambridge, Massa-
chusetts 02139 (US). DULAK, Austin; c/o Surface Oncol-
ogy, Inc., 50 Hampshire Street, 8th Fl., Cambridge, Massa-
chusetts 02139 (US). SMITH, Ernest; c/o Vaccinex, Inc.,
1895 Mount Hope Avenue, Rochester, New York 14620
(US). SCRIVENS, Maria; c/o Vaccinex, Inc., 1895 Mount
Hope Avenue, Rochester, New York 14620 (US). HAR-
VEY, Carrie; c/o Vaccinex, Inc., 1895 Mount Hope Av-
enue, Rochester, New York 14620 (US). KIRK, Renee;
c/o Vaccinex, Inc., 1895 Mount Hope Avenue, Rochester,
New York 14620 (US). BALCH, Leslie; c/o Vaccinex,
Inc., 1895 Mount Hope Avenue, Rochester, New York
14620 (US). DAS, Sonia G.; c/o Surface Oncology, Inc., 50
Hampshire Street, 8th Fl., Cambridge, Massachusetts 02139
(US). WELLS, Christopher Converse; c/o Surface Oncol-
ogy, Inc., 50 Hampshire Street, 8th Fl., Cambridge, Massa-
chusetts 02139 (US).

(74) Agent: KIM, Ji Eun et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: ANTI-CCR8 ANTIBODIES AND USES THEREOF

(57) Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

WO 2021/142002 A1